Swiss National Bank Has $17.22 Million Position in Penumbra, Inc. (NYSE:PEN)

Swiss National Bank raised its position in shares of Penumbra, Inc. (NYSE:PEN) by 0.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 72,500 shares of the company’s stock after purchasing an additional 600 shares during the quarter. Swiss National Bank owned 0.19% of Penumbra worth $17,217,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in PEN. Janus Henderson Group PLC raised its stake in Penumbra by 128.1% during the 3rd quarter. Janus Henderson Group PLC now owns 668,873 shares of the company’s stock valued at $129,967,000 after purchasing an additional 375,684 shares during the period. Champlain Investment Partners LLC raised its stake in Penumbra by 20.6% during the 3rd quarter. Champlain Investment Partners LLC now owns 1,547,972 shares of the company’s stock valued at $300,786,000 after purchasing an additional 264,122 shares during the period. Massachusetts Financial Services Co. MA acquired a new stake in Penumbra during the 3rd quarter valued at $31,965,000. Braidwell LP raised its stake in Penumbra by 70.0% during the 3rd quarter. Braidwell LP now owns 361,428 shares of the company’s stock valued at $70,229,000 after purchasing an additional 148,834 shares during the period. Finally, Baillie Gifford & Co. raised its stake in Penumbra by 23.4% during the 4th quarter. Baillie Gifford & Co. now owns 730,233 shares of the company’s stock valued at $173,416,000 after purchasing an additional 138,387 shares during the period. 88.88% of the stock is owned by institutional investors and hedge funds.

Penumbra Stock Down 0.2 %

PEN stock opened at $275.40 on Wednesday. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.01 and a quick ratio of 3.25. Penumbra, Inc. has a 52-week low of $148.00 and a 52-week high of $310.00. The company has a 50-day moving average of $271.17 and a two-hundred day moving average of $238.92. The stock has a market capitalization of $10.61 billion, a price-to-earnings ratio of 810.01, a price-to-earnings-growth ratio of 2.83 and a beta of 0.51.

Penumbra (NYSE:PEN) last released its quarterly earnings results on Tuesday, February 18th. The company reported $0.97 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.88 by $0.09. Penumbra had a net margin of 1.17% and a return on equity of 9.74%. The company had revenue of $315.52 million during the quarter, compared to analysts’ expectations of $311.63 million. As a group, equities research analysts anticipate that Penumbra, Inc. will post 3.67 EPS for the current year.

Insider Buying and Selling at Penumbra

In related news, CFO Maggie Yuen sold 2,000 shares of the stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $286.00, for a total value of $572,000.00. Following the completion of the sale, the chief financial officer now owns 15,243 shares in the company, valued at approximately $4,359,498. This trade represents a 11.60 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Adam Elsesser sold 61,600 shares of the stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $283.59, for a total transaction of $17,469,144.00. Following the completion of the sale, the chief executive officer now owns 16,376 shares of the company’s stock, valued at approximately $4,644,069.84. The trade was a 79.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 79,918 shares of company stock worth $22,054,293 over the last ninety days. Company insiders own 5.00% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on PEN. Oppenheimer began coverage on shares of Penumbra in a research note on Tuesday, December 17th. They issued an “outperform” rating and a $275.00 price target on the stock. Citigroup upped their price target on shares of Penumbra from $220.00 to $245.00 and gave the stock a “neutral” rating in a research note on Wednesday, December 11th. Truist Financial upped their price target on shares of Penumbra from $285.00 to $325.00 and gave the stock a “buy” rating in a research note on Wednesday, February 19th. UBS Group upped their price target on shares of Penumbra from $305.00 to $320.00 and gave the stock a “buy” rating in a research note on Wednesday, February 19th. Finally, Canaccord Genuity Group upped their price target on shares of Penumbra from $323.00 to $340.00 and gave the stock a “buy” rating in a research note on Wednesday, February 19th. Four analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $294.47.

About Penumbra

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.